骨癌：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 德国骨癌市场预计将从 2025 年的 2,700 万美元成长到 2035 年的 4,500 万美元，复合年增长率为 5%，这主要得益于渐进式创新和治疗可及性的提高。
• 发病率的成长仍然很低（年复合成长率约为 1-1.5%），这表明：疾病负担稳定，市场扩张是由治疗方法创新驱动的，而不是患者数量的增加。

骨癌概述

骨癌是一种高度侵袭性的原发性恶性骨肿瘤，其特征是恶性间质细胞产生类似骨骼的物质。它主要发生于青少年和青年人，通常发生于长骨的干骺端，例如股骨远端和胫骨近端。

患者通常主诉局部骨痛和肿胀，夜间症状常加重。此病极易早期转移，尤其是肺部转移，会显着影响预后。

标准治疗方案包括多方面措施，例如：

• 术前多药化疗
• 手术切除（通常是保肢手术）
• 术后化疗

治疗效果很大程度取决于化疗的组织学反应以及诊断时是否有转移。即使采取积极治疗，转移性或復发性病例的生存率仍然很低，这表明存在巨大的未满足医疗需求。

主要亮点

• 在美国，预计新增病例数将从 2025 年的 2000 例增加到 2035 年的 2,200 例，反映出较低的成长率（年复合成长率为 1-1.5%）。
• 此疾病的负担是由以下因素造成的：诊断时转移率高，以及復发和难治性病例的治疗选择有限。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Hansoh BioMedical R&D;Company
• MedPacto, Inc.
• Emerald Clinical Inc.
• Tcelltech Inc.
• Circle Pharma
• Cellectar Biosciences, Inc.
• Jazz Pharmaceuticals
• Inhibrx Biosciences, Inc
• Valo Therapeutics Oy
• Amgen
• Eli Lilly and Company
• Shanghai Pharmaceuticals Holding Co., Ltd
• GlaxoSmithKline
• Hangzhou DAC Biotechnology Co., Ltd.
• Iovance Biotherapeutics, Inc.
• USWM CT, LLC
• UNICANCER
• Valent Technologies, LLC
• SEED Therapeutics, Inc.
• Actuate Therapeutics Inc.
• Pfizer
• Merck Sharp &Dohme LLC
• Endeavor Biomedicines, Inc.
• Hoffmann-La Roche

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物分类的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
• 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期研发管线

第六章：未满足的需求与目标产品分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Osteosarcoma Market Outlook

Thelansis's "Osteosarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Osteosarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Osteosarcoma Overview

Osteosarcoma is a highly aggressive primary malignant bone tumor characterized by the production of osteoid by malignant mesenchymal cells. It predominantly affects adolescents and young adults, typically arising in the metaphyseal regions of long bones such as the distal femur and proximal tibia.

Patients commonly present with localized bone pain and swelling, often worsening at night. The disease has a strong propensity for early metastasis, particularly to the lungs, which significantly impacts prognosis.

The standard of care involves a multimodal approach, including:

• Neoadjuvant multi-agent chemotherapy
• Surgical resection (often limb-salvage procedures)
• Adjuvant chemotherapy

Outcomes are heavily dependent on histological response to chemotherapy and metastatic status at diagnosis. Despite aggressive treatment, survival rates for metastatic or relapsed disease remain poor, highlighting significant unmet need.

Key Highlights

• In the United States, incident cases are projected to increase from 2.0K in 2025 to 2.2K by 2035, reflecting a low growth rate (1-1.5% CAGR).
• Disease burden is driven by: High rates of metastasis at diagnosis & Limited treatment options in relapsed/refractory settings

Market Overview

• The osteosarcoma market in Germany is projected to grow from $27M in 2025 to $45M by 2035, reflecting a CAGR of 5%, driven by incremental innovation and improved treatment access.
• Incidence growth remains low (~1-1.5% CAGR), indicating: Stable disease burden & Market expansion driven by treatment innovation rather than patient volume

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Hansoh BioMedical R&D Company
• MedPacto, Inc.
• Emerald Clinical Inc.
• Tcelltech Inc.
• Circle Pharma
• Cellectar Biosciences, Inc.
• Jazz Pharmaceuticals
• Inhibrx Biosciences, Inc
• Valo Therapeutics Oy
• Amgen
• Eli Lilly and Company
• Shanghai Pharmaceuticals Holding Co., Ltd
• GlaxoSmithKline
• Hangzhou DAC Biotechnology Co., Ltd.
• Iovance Biotherapeutics, Inc.
• USWM CT, LLC
• UNICANCER
• Valent Technologies, LLC
• SEED Therapeutics, Inc.
• Actuate Therapeutics Inc.
• Pfizer
• Merck Sharp & Dohme LLC
• Endeavor Biomedicines, Inc.
• Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)